Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 6th and 7th, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on February 6, 2025, at a weighted average price of $12.85.
- An additional 2,000 shares were sold on February 7, 2025, at a weighted average price of $12.16.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these transactions, Ma directly owns no shares and indirectly owns 2,879,158 shares through his spouse.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock sales by an insider under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the regulatory landscape, providing transparency into the trading activities of company insiders. The use of a 10b5-1 plan suggests that these sales were pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The stock sales could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2024-09-13 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-02-06 | Date of first stock sale |
| 2025-02-07 | Date of second stock sale |
| 2025-02-11 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.